The catalyst: CMS's CY2026 OPPS final rule (effective January 1) extends "site-neutral" payment to drug-administration services at off-campus hospital outpatient departments, cutting those payments to the Physician Fee Schedule-equivalent rate — roughly 40% of what hospitals previously billed Medicare for the identical infusion given across town at a doctor's office. CMS projects ~$290 million in 2026 savings alone, and Congress's bipartisan "Same Care, Lower Cost Act" would go much further, forcing HOPD-wide parity and mandatory separate NPI billing for off-campus sites by 2028. The mechanism is simple: Medicare currently pays a facility fee premium — often 2-3x the physician-office rate — for the exact same visit, injection, or scan, purely because a hospital bought the clinic and slapped its name on the building. Close that gap and you delete a recurring, structural revenue stream that hospital-owned outpatient networks have spent two decades building via acquisition.
Who is exposed: HCA (HCA) is the epicenter. As the largest U.S. for-profit hospital operator, HCA has aggressively rolled up physician practices and freestanding clinics into hospital-outpatient billing designations specifically to capture the facility-fee premium — it's a core, durable piece of its outpatient margin, not a footnote. Site-neutral parity directly compresses that spread across hundreds of HCA-affiliated sites, which is why CEO Sam Hazen personally testified before House Ways and Means in April, offering only conditional concessions ("merit to hospitals receiving a premium in certain circumstances") rather than capitulation. HCA and its trade group, the American Hospital Association, have poured lobbying dollars into slowing or narrowing every version of this policy — spending patterns that mark HCA as the single most exposed name in the fight, more than any insurer.